07:56 AM EST, 01/30/2025 (MT Newswires) -- Merck ( MRK ) said Thursday that its late-stage study evaluating winrevair against placebo in adults recently diagnosed with pulmonary arterial hypertension functional class II or III at intermediate or high risk of disease progression will be stopped early.

The company said the decision to stop the study was based on the positive results of the interim analysis of another late-stage trial known as Zenith, as well as review of all data from the winrevair clinical program to date.

Merck ( MRK ) said findings from the study will be available later this year and presented at a future medical congress.